Navigation Links
Change in PSA level does not predict prostate cancer
Date:2/24/2011

NEW YORK, February 24, 2011 Researchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time known as PSA velocity is a poor predictor of prostate cancer and may lead to many unnecessary biopsies. The new study of more than 5,000 men was published online February 24 in the Journal of the National Cancer Institute. Andrew Vickers, PhD, Associate Attending Research Methodologist in the Department of Epidemiology and Biostatistics and lead author said, "We have found no evidence to support the recommendation that men with a high PSA velocity should be biopsied in the absence of other indications. In other words, if a man's PSA has risen rapidly in recent years, there is no cause for concern if his total PSA level is still low and his clinical exam is normal."

Prostate cancer is the most common cancer among American men and the second leading cause of cancer deaths in men, according to the American Cancer Society. While PSA screening is widely used for the early detection of prostate cancer, it is also associated with a high rate of overdiagnosis, which can lead to unnecessary treatment and anxiety. Currently, early detection guidelines of several organizations (the National Cancer Center Network and the American Urological Association) recommend that men with a rapid rise in PSA or a high PSA velocity have a surgical biopsy for prostate cancer, even if there are no other indicators that cancer may exist. Those indicators could be an elevated baseline PSA or a positive digital rectal exam (DRE).

This study's population came from the Prostate Cancer Prevention Trial. Five thousand five hundred and nineteen men aged 55 years and older with no previous prostate cancer diagnosis, normal DRE, and a baseline PSA of 3.0 ng/mL or less were randomly assigned to finasteride a drug commonly used to treat enlargement of the prostate gland, more commonly referred to as BPH, or benign prostatic hypertrophy or placebo for seven years. This particular study focused on the men in the placebo group. The men were followed with yearly PSA tests, with biopsy recommended for men with a PSA higher than 4.0 ng/mL. After seven years, all men who were not diagnosed with prostate cancer were asked to consent to an end-of-study biopsy.

Dr. Vickers and colleagues found no important association between PSA velocity and biopsy outcome after adjusting for risk factors such as age, race, and PSA levels. PSA alone was a much better predictor of biopsy outcome than PSA velocity.

According to Peter T. Scardino, MD, Chair of the Department of Surgery, "This study should change practice. We have previously published papers determining that PSA naturally varies from month to month and have urged men whose PSA suddenly rises to wait six weeks and repeat the test before agreeing to a needle biopsy. This new study in a large population of men provides even stronger evidence that using changes in PSA as a basis for recommendation for biopsy leads to many more unnecessary biopsies and does not help to find the more aggressive cancers that we want to find and treat." Dr. Scardino added that "men should be cautious before rushing into a biopsy for minor variations in their PSA level."


'/>"/>

Contact: Courtney DeNicola Nowak
denicolc@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Physical Changes in Brain Linked to Altered Spirituality
2. Whitemark Homes Inc. Announces Change of Auditors and Additional Corporate Information
3. Apptix Signs 100,000 Seat Hosted Exchange Email Contract
4. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
5. Tyco International Announces Exchange Rate for Quarterly Dividend
6. MARC Coalition Applauds Agencys Alert Regarding Delay in Data Exchange Deadline
7. Medicare Advantage Members May Make Changes During Open Enrollment
8. Clearwave Corporation Creates Healthcare's First Patient-Facing Network Exchange
9. CMS Watch Changes Name to The Real Story Group
10. Changes during menopause increases risk of heart disease and stroke
11. Access to Mammograms Drops After Guidelines Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... of a new CDISC standard, Clinical Trial Registry (CTR) XML. Clinical trial ... standard will make it possible to build applications that generate submissions for ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... and the Campaign for Tobacco-Free Kids, a leading force in the fight to ... federal, state and local policies that can help reduce tobacco use. The initiative ...
(Date:4/28/2016)... ... 2016 , ... In 2011, TIME magazine named Herr the “Leader of the ... that marries human physiology with electromechanics. He continues that work as Director of the ... BionX , a leader in the field of prosthetic devices. , After a ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cognizin® Citicoline ... 2016. , Nominated in the Healthy Ageing category, Cognizin® is being considered for ... Healthy Ageing division can include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients ...
(Date:4/28/2016)... ... , ... USA Medical Card reminds us that May is National Stroke Awareness Month. According ... cause of death in the United States; someone has one every 40 seconds. Annually, ... under 65 years old. A stroke is when blood flow to the brain is ...
Breaking Medicine News(10 mins):
(Date:4/26/2016)... , April 26, 2016 Hill-Rom Holdings, Inc. (NYSE: ... management presentation at the Deutsche Bank 41 st Annual ... p.m. EDT. You are invited to listen to ... or access it directly at http://edge.media-server.com/m/p/mr4uxgas . A ... after conclusion of the live event and accessible at the ...
(Date:4/26/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... is projected to grow at a CAGR of 10.38% ... a technique that involves measurement and analysis of DNA ... in biochemical pathways. The aim of performing these tests ...
(Date:4/26/2016)... 26, 2016 Bayer AG has ... taxes, depreciation and amortization. The earnings are the result ... best-selling drugs Xarelto and Eylea, drugs Bayer is banking ... patent expiration date was extended by four years this ... is expected to reach a value of USD ...
Breaking Medicine Technology: